SCHEMBL31023940

SCHEMBL31023940

O=C(N1CCCCC1)N1CCN(C(c2ccc3c(c2)COCO3)c2ccc3c(c2)COCO3)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.52
KMT2A Q03164 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
ALDH1A1 P00352 4/20 0.44
P4HB P07237 4/20 0.43
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
SMAD3 P84022 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HSD17B10 Q99714 1/20 0.37
FAAH O00519 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
TRPV1 Q8NER1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023723 0.87 SMAD3 (0.42) HPGDKMT2AKDM4EMAPTNPSR1
SCHEMBL31023824 0.85 ALDH1A1 (0.39) HPGDKMT2AKDM4EMAPTNPSR1
SCHEMBL31023802 0.83 MGLL (0.39) HPGDKMT2AKDM4EMAPTNPSR1
SCHEMBL31023826 0.82 FAAH (0.58) HPGDKMT2AKDM4EMAPTNPSR1
SCHEMBL31023905 0.82 MGLL (0.59) FAAH
SCHEMBL31023796 0.82 CNR1 (0.38) NPSR1P4HBCNR1CNR2SMAD3
SCHEMBL31023669 0.82 FAAH (0.40) HPGDKMT2AKDM4EMAPTNPSR1
SCHEMBL31023863 0.81 SCD5 (0.41) KMT2AMAPTALDH1A1P4HBSMAD3
SCHEMBL31023999 0.80 OPRD1 (0.44) KMT2ASMAD3MEN1
SCHEMBL31023944 0.80 SCD5 (0.44) KMT2AMAPTALDH1A1SMAD3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US claimed
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL HPGD 1304/4885KMT2A 1730/4885KDM4E 2756/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL HPGD 1304/4885KMT2A 1730/4885KDM4E 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.